Track topics on Twitter Track topics that are important to you
Astellas Pharma had only signed an exclusive licensing deal with Universal Cells back in October for the co-development of a particular drug candidate utilising the latter company’s technology, four months later Astellas has returned to buyout the company.
Clearly, Astellas liked what it saw during the exploratory deal to use Universal Cells’ proprietary Universal Donor Cell technology – this sees the biotech able to create cell therapy products that do not require Human Leukocyte antigen matching.
Original Article: Astellas scoops up Universal Cells for $102.5mNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...